Immune Suppression Of Infants Treated With Steroids
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00433940|
Recruitment Status : Completed
First Posted : February 12, 2007
Last Update Posted : January 24, 2013
|Condition or disease||Intervention/treatment|
|Study Type :||Observational|
|Actual Enrollment :||16 participants|
|Official Title:||Immune Suppression of Infants Treated With Oral Corticosteroids for Infantile Hemangiomas: A Pilot Study|
|Study Start Date :||October 2006|
|Actual Primary Completion Date :||April 2008|
|Actual Study Completion Date :||July 2010|
Infantile Hemangioma Patients
Infants with infantile hemangioma being treated clinically with oral prednisolone sodium phosphate suspensions.
Oral prednisolone sodium phosphate suspension administered in dosage of 15mg/5mL. Medication administered every morning at a starting daily dose of 2.5mg/kg.
Other Name: steroid
- Lymphocyte Subtest of Complete Blood Count Analysis (Primary Immunodeficiency) [ Time Frame: 2 years ]Measurement of absolute lymphocyte count and % lymphocyte found during a Complete Blood Count analysis.
Biospecimen Retention: None Retained
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00433940
|United States, Wisconsin|
|Children's Hospital of Wisconsin|
|Milwaukee, Wisconsin, United States, 53226|
|Principal Investigator:||Beth A Drolet, MD||Medical College of Wisconsin|